GlobalData on MSN1d
Aardvark prices $94.2m IPO to fund development of Prader-Willi syndrome drugAardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.
Biomedical engineers at Duke University have demonstrated a promising new approach that could be used to treat a rare and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback